Ingalls & Snyder LLC
PDLI

Ingalls & Snyder LLC’s PDL BioPharma, Inc. PDLI Stock Holding History

Ingalls & Snyder LLC’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-25,600
Closed -$204K – 364
2013
Q3 		$204K Sell
25,600
-23,100
-47% -$186K 0.01% 315
2013
Q2 		$375K Buy
+48,700
New +$380K 0.02% 255

Other funds holding PDLI

Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock Fund Advisors
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return
BlackRock Institutional Trust
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Gotham Asset Management
Gotham Asset Management New York $43B AUM 34.97% 1-Year Est. Return
Advisors Asset Management
Advisors Asset Management Monument, Colorado $6.56B AUM 35.09% 1-Year Est. Return

Ingalls & Snyder LLC's PDLI Position: Q4 2013 in Review

Ingalls & Snyder LLC sold out of PDL BioPharma, Inc. (PDLI) in Q4 2013, closing a stake of 25,600 shares — an estimated $204K sold.

Ingalls & Snyder LLC first reported a position in PDLI in Q2 2013 and held it in 2 quarters. The position peaked at $375K in Q2 2013. 224 funds tracked by Wall St. Rank hold PDLI as of Q4 2013.

  • Ingalls & Snyder LLC reported no remaining PDL BioPharma, Inc. position as of Q4 2013 after selling out during the quarter.
  • Ingalls & Snyder LLC sold 25,600 PDL BioPharma, Inc. shares in Q4 2013, an estimated $204K.
  • Ingalls & Snyder LLC first reported a position in PDL BioPharma, Inc. in Q2 2013 and held it in 2 quarters.
  • Ingalls & Snyder LLC's PDL BioPharma, Inc. position peaked at $375K in Q2 2013.
  • 224 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q4 2013.

Based on Ingalls & Snyder LLC's 13F filing for Q4 2013, filed 24 Jan 2014.